遗传增强
疾病
临床试验
清脆的
生物信息学
生物
医学
基因
重症监护医学
遗传学
病理
作者
Matthew R. Cring,Val C. Sheffield
出处
期刊:Gene Therapy
[Springer Nature]
日期:2020-10-09
卷期号:29 (1-2): 3-12
被引量:77
标识
DOI:10.1038/s41434-020-00197-8
摘要
The field of gene therapy has made significant strides over the last several decades toward the treatment of previously untreatable genetic disease. Gene therapy techniques have been aimed at mitigating disease features of recessive and dominant disorders, as well as several cancers and other diseases. While there have been numerous disease targets of gene therapy trials, only four therapies have reached FDA and/or EMA approval for clinical use. Gene correction using CRISPR-Cas9 is an extension of gene therapy that has received considerable attention in recent years and boasts many possible uses beyond classical gene therapy approaches. While there is significant therapeutic potential using gene therapy and gene correction strategies, a number of hurdles remain to be overcome before they become more common in clinical use, particularly with regards to safety and efficacy. As research progresses in this exciting field, it is likely that these therapies will become first-line treatments and will have tremendous positive impacts on the lives of patients with genetic disorders.
科研通智能强力驱动
Strongly Powered by AbleSci AI